Search results
Results from the WOW.Com Content Network
ITCLD-GT occurs more commonly in males of middle age (median age 48.4, range 15–77 years in one study). [2] Individuals with the disease present with GI tract symptoms which often are serious and/or debilitating [9] and may mimic those occurring in malignant lymphoproliferative, inflammatory, or autoimmune bowel diseases. [4]
T-cell lymphoma is a rare form of cancerous lymphoma affecting T-cells. [1] Lymphoma arises mainly from the uncontrolled proliferation of lymphocytes, such as T-cells, and can become cancerous. [2] T-cell lymphoma is categorized under Non-Hodgkin lymphoma (NHL) and represents less than 15% of all Non-Hodgkin's diseases in the category. [3]
In TLS, the breakdown occurs after cytotoxic therapy or from cancers with high cell turnover and tumor proliferation rates. [4] The metabolic abnormalities seen in tumor lysis syndrome can ultimately result in serious complications such as acute uric acid nephropathy , acute kidney failure , seizures , cardiac arrhythmias , and death.
Alternatively, fatty acids can be converted to lipid intermediates like diacylglycerol, ceramides and fatty acyl-CoAs. These lipid intermediates can impair cellular function, which is referred to as lipotoxicity. [2] Adipocytes, the cells that normally function as lipid store of the body, are well equipped to handle the excess lipids. Yet, too ...
Adult T-cell leukemia/lymphoma (ATL or ATLL) is a rare cancer of the immune system's T-cells [1] [2] [3] caused by human T cell leukemia/lymphotropic virus type 1 . [4] All ATL cells contain integrated HTLV-1 provirus further supporting that causal role of the virus in the cause of the neoplasm. [ 4 ]
A major application of cellular adoptive therapy is cancer treatment, as the immune system plays a vital role in the development and growth of cancer. [1] The primary types of cellular adoptive immunotherapies are T cell therapies. Other therapies include CAR-T therapy, CAR-NK therapy, macrophage-based immunotherapy and dendritic cell therapy.
Cutaneous T-cell lymphoma (CTCL) is a class of non-Hodgkin lymphoma, which is a type of cancer of the immune system. Unlike most non-Hodgkin lymphomas (which are generally B-cell-related), CTCL is caused by a mutation of T cells. The cancerous T cells in the body initially migrate to the skin, causing various lesions to appear.
Fat embolism syndrome occurs when fat enters the blood stream (fat embolism) and results in symptoms. [1] Symptoms generally begin within a day. [1] This may include a petechial rash, decreased level of consciousness, and shortness of breath. [1] Other symptoms may include fever and decreased urine output. [2] The risk of death is about 10%. [2]